A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2022-04-07
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-05-21 (study day 29); relationship: Y
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-06-01 (study day 40); relationship: Y
mild
assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-17 (study day 209); relationship: not assessed
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-10 (study day 232); relationship: not assessed
Data queries
No data queries.